TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatitis C virus (HCV) genotype 1 infection (confirmed at screening).~* HCV ribonucleic acid (RNA) greater than 10,000 IU/mL at screening~* Treatment-experienced participants must have at least 1 documented previous course of interferon-based regimen with or without ribavirin~* Participants must have an hepatic imaging procedure (ultrasound, computerized tomography scan or magnetic resonance imaging scan) within 6 months prior to the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma~* Participant must be willing and able to comply with the protocol requirements~* Participants with liver cirrhosis~Exclusion Criteria:~* Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)~* Infection/co-infection with HCV non-genotype 1~* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)~* Co-infection with hepatitis B virus (hepatitis B-surface-antigen positive)~* Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Simeprevir/Sofosbuvir) (Type: EXPERIMENTAL): 100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FACBC Outcomes for Post Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the prostate, post radical-prostatectomy Detectable PSA~* ECOG/Zubrod Performance Status of 0-2~* Negative technetium 99-m MDP or F-18 PET bone scan for skeletal metastasis~* CT or MR scan of abdomen and pelvis which does not suggest presence of metastatic disease outside of the pelvis~* Willingness to undergo pelvic radiotherapy.~Exclusion Criteria:~* Contraindications to radiotherapy (including active inflammatory bowel disease or prior pelvic XRT)~* Inability to undergo anti-3-\[18F\]FACBC PET-CT~* Age under 18~* Metastatic disease outside of pelvis on any imaging or biopsy~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years~* Severe acute co-morbidity, defined as follows:~  * Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months~ * Transmural myocardial infarction within the last 6 months~ * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration~ * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration~ * Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immunocompromised patients

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- FACBC PET scan (Type: EXPERIMENTAL): A trial group in which anti-3-\[18F\]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
- Conventional-Only Imaging (Type: ACTIVE_COMPARATOR): A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes (T2D) mellitus greater than equal to (≥) 180 days before screening.~* Stable daily dose(s) ≥ 90 days prior to the day of screening of metformin ≥ 1500 milligrams (mg) or maximum tolerated or effective dose.~* HbA1c of 7.0-10.5 percentage (%) \[53-91.3 millimoles per mole (mmol/mol)\] (both inclusive).~Exclusion Criteria:~* Known or suspected hypersensitivity to study intervention(s) or related products.~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed.~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for nondilated examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide J (Type: EXPERIMENTAL): Participants will initially receive 0.25 milligrams (mg) subcutaneous injections of semaglutide J once weekly (OW) and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.
- Semaglutide B (Type: ACTIVE_COMPARATOR): Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with type 2 diabetes mellitus~* Substudy inclusion criteria:~  * Completion of the 6-month study period in main study (Visit 10)~ * Randomized and treated with insulin glargine new formulation during the 6-month treatment period (Baseline - month 6)~Exclusion criteria:~* Age less than (\<) 18 years~* HbA1c \<7.0% or greater than (\>) 10% at screening~* Diabetes other than type 2 diabetes mellitus~* Less than 1 year on basal plus mealtime insulin and self-monitoring of blood glucose~* Any contraindication to use of insulin glargine as defined in the national product label~* Participants using human regular insulin as mealtime insulin in the last 3 months before screening visit~* Use of an insulin pump in the last 6 months before screening visit~* Initiation of new glucose-lowering agents and/or weight loss drugs in the last 3 months before screening visit~* History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period~* Pregnant or breast-feeding women or women who intend to become pregnant during the study period~* Substudy exclusion criteria:~  * Participant not willing to use the adaptable injection intervals on at least two days per week~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HOE901-U300 (Type: EXPERIMENTAL): None
- Lantus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
The study population consisted of patients with a documented history of episodic (4 - 14 baseline migraine days) or chronic migraine (≥15 baseline headache days), who had been successfully randomized to clinical trial CAMG334ADE01.~Key inclusion Criteria:~* Signed informed consent must be obtained prior to participation in the study~* Patient is capable of understanding the nature, significance and implications of the clinical trial.~* Adults ≥18 years of age upon entry into screening~Key exclusion Criteria:~* Use of a prophylactic migraine medication within five plasma clearance half-lives, or a device or procedure within one month prior to the start of the Open-label Treatment Epoch. This exclusion criteria does not apply to erenumab or topiramate administered within clinical trial CAMG334ADE01~* Any prior exposure to (investigational) prophylactic migraine products targeting the CGRP pathway, other than erenumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 67 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): Erenumab dose could be adjusted from 70 mg to 140 mg or vice versa at the discretion of the physician at any scheduled study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CRF - Nociceptin Receptor Interactions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 40 years old~Exclusion Criteria:~* Current DSM-5 psychiatric disorders~* Binge drinking as defined in NIAAA criteria in the past month~* Recreational abuse of opiates, sedative-hypnotics, cocaine, amphetamines, MDMA, and PCP, as well as cannabis use~* Currently on any prescription medical or psychotropic medication;~* Current or past severe medical, endocrine, cardiovascular, immunological or neurological illnesses~* Currently pregnant or breast-feeding;~* History of radioactivity exposure via prior nuclear medicine studies or occupational exposure in past twelve months~* Metallic objects in the body that are contraindicated for MRI;~* First-degree relative with psychosis or mood disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- [C-11]NOP-1A PET Scan conditions (Type: EXPERIMENTAL): Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. To have been diagnosed MS Remittent Recurrent according to Mc Donald 20052 criteria.~2. To have an EDSS between 0 and 5 before the relapse.~3. The symptoms have begun after at least one month of previous stability.~4. The symptoms have started maximum 15 days before the inclusion.~5. The patient is capable of having an adequate communication with the investigator and to carry out with the clinical trial requisites.~6. To be or not to be with allowed immunomodulatory therapy (IFN-B /AG).~7. To be capable and to be willing to ingest the medication.~Exclusion Criteria:~1. First inflammatory neurological episode (relapse).~2. Multiple sclerosis secondary progressive or primary progressive.~3. The symptoms have gone on for less than 24 hours.~4. To be in treatment or have been treated with corticoids during the three months before.~5. Patients in treatment with immunosuppressors (azathioprine, mitoxantrone, ciclofosfamide...)~6. Pregnancy or breastfeeding or women in fertile age who don't use contraceptives measurements.~7. Illnesses with contraindication treatment with corticoids.~8. Antecedents of serious adverse effects or hypersensitive to related study medication.~9. Patients who wouldn´t be able to perform periodic RMN explorations, patients who are not collaborative or who need anesthesia.~10. Patients with intolerance to lactose.~11. Patients with allergy to contrast used in RMN.~12. Patients with chronic kidney disease.~13. Patients in treatment with natalizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
- 2 (Type: EXPERIMENTAL): methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Zinc in Infant Bacterial Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Evidence of possible serious bacterial infection, defined as a CRP \>= 12 mg/L and any one of the following clinical features:~Fever (axillary temperature \>= 37.5 degrees C) or hypothermia (axillary temperature \<35.5 degrees C).~Lethargic or unconscious. No attachment to the breast in breast fed infants. No suckling in breast fed infants. Convulsions in the present episode. Bulging fontanel.~* History of acute refusal of feed in the present episode.~* Acute history of excessive cry or irritability in the present episode.~* Fast breathing defined as \>= 60 breaths/minute (on second count) for infants \< 2 months and \>= 50 breaths/min in infants 2 months up to 4 months.~* Grunting in the absence of any non infective cause.~* Cyanosis in the absence of any non infective cause.~* Severe chest in drawing.~* Unexplained shock.~* Diarrhea in present episode.~Exclusion Criteria:~* Congenital malformations e.g. hydrocephalus, structural CNS malformation.~* Severe birth asphyxia defined as:~  * One minute APGAR (if available) of \< 4/10.~ * CT scan or MRI or EEG abnormalities if available suggestive of hypoxic ischemic encephalopathy.~* Known structural defects, which interfere with feeding, e.g.cleft palate esophageal abnormalities, intestinal atresia and stenosis, malrotation of the gut,anorectal malformation.~* Subjects requiring ventilation or ionotropic support.~* History of diarrhea in the present episode.~* Known inborn error of metabolism.~* Chronic disorders of other organs e.g. neonatal cholestasis, chronic renal failure, pre-existing seizure disorder.~* Infants born of known HIV mothers.~* Clinical suspicion of necrotising enterocolitis.~* Congenital heart disease.~* Any CVS malformation:~  * Congenital heart disease.~ * Cyanosis before present episode.~ * Presence of murmur \> grade 3/6.~* Ambiguous genitalia.~* Known chromosomal abnormality.~* Infants requiring exchange transfusion.

- Gender: ALL
- Minimum Age: 1 Week
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Zinc (Type: EXPERIMENTAL): Administration of zinc sulphate every day during illness
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 - 65 years of age~* First histologic diagnosis of MCNS~* Proteinuria \> 3.5 g/day~* Patients who are willing to give written, informed consent~Exclusion Criteria:~* Presence of secondary causes of MCNS~* History of glomerular disease including MCNS~* eGFR \< 50 ml/min/1.73m2~* Renal histology showing pathologies other than MCNS~* Female of child-bearing age who are unwilling to practice effective contraception~* Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Myfortic plus low-dose steroid (Type: EXPERIMENTAL): Not necessary
- Standard-dose steroid (Type: ACTIVE_COMPARATOR): Not necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants. \>/= 18 years of age~* Histologically confirmed metastatic or unresectable papillary thyroid cancer for which standard curative or palliative measures do not exist or are no longer effective; participants whose tumors exhibit areas of other histology may be enrolled, provided the tumor histology remains predominantly papillary~* Positive for BRAF V600 mutation (Roche Cobas 4800 BRAF V600 Mutation Test)~* Radioactive Iodine resistant disease~* Prior therapy excluding (Cohort 1, TKI Naive) or including (Cohort 2, TKI Experienced) TKI~* Clinically relevant disease progression according to RECIST criteria within the prior 14 months~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Adequate hematological, renal and liver function~Exclusion Criteria:~* Histological diagnosis other than papillary PTC, including squamous cell variants of PTC or PTC with areas of squamous metaplasia~* Active or untreated central nervous system metastases~* History of or known carcinomatous meningitis~* Anticipated or ongoing administration of any anti-cancer therapies other than those administered in the study~* Active squamous cell skin cancer that has not been excised or adequately healed post excision~* Previous treatment with any agent that specifically and selectively targets the MEK or BRAF pathway~* Prior radiotherapy to the only measurable lesion~* Clinically relevant cardio-vascular disease or event within the prior 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tyrosine Kinase Inhibitor (TKI) Naive (Type: EXPERIMENTAL): Vemurafenib in participants naive to any prior systemic TKI therapy.
- TKI Experienced (Type: EXPERIMENTAL): Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 70 years or older.~* Patients with hypertension prior to being randomized into study.~* Patients must have an office cuff MSSBP ≥ 140 and ≤ 200 mmHg systolic.~* Have the ability to communicate and comply with all study requirements.~* Provide written informed consent to participate in the study prior to any screening or study procedures.~Exclusion Criteria:~* Use of other investigational drugs within 30 days of enrollment.~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~* Office blood pressure measured by office machine cuff with a mean of (3) MSDBP ≥ 120 mmHg at anytime during the screening / washout period.~* Patients taking 3 or more antihypertensive drugs and MSSBP ≥ 160 mmHg at the time of Visit 1.~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valsartan (Type: ACTIVE_COMPARATOR): (patients initiated on valsartan)
- HCTZ (Type: ACTIVE_COMPARATOR): (patients initiated on HCTZ)
- Valsartan + HCTZ (Type: EXPERIMENTAL): (patients initiated on Valsartan+HCTZ)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete